Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting
| Autor: | Fran Robson, Palma Rocchi, Sinem Demirbag, Thi Khanh Le, Khadija Shahed Khan, Clément Paris, Peter Barfuss, Wai-Lung Ng |
|---|---|
| Přispěvatelé: | University of Bristol [Bristol], The Chinese University of Hong Kong [Hong Kong], Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Hanoi University of Science and Technology (HUST), Sabanci University, Nanotechnology Research and Application Center, Sabanci University [Istanbul], Université Paris-Est (UPE), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Rocchi, Palma |
| Rok vydání: | 2020 |
| Předmět: |
antisense oligonucleotide
Transcription Genetic MESH: Coronavirus Infections viruses [SDV]Life Sciences [q-bio] Cell coronavirus Cytidine Viral Nonstructural Proteins medicine.disease_cause Virus Replication Genome Severity of Illness Index 0302 clinical medicine Transcription (biology) MESH: Molecular Targeted Therapy MESH: COVID-19 Nucleotide MESH: Adenosine Monophosphate Molecular Targeted Therapy Coronavirus chemistry.chemical_classification 0303 health sciences Alanine non-structural protein 14 virus diseases ExoN MESH: Amides 3. Good health [SDV] Life Sciences [q-bio] medicine.anatomical_structure 030220 oncology & carcinogenesis MESH: Pyrazines MESH: RNA Viral Pyrazines Proofreading MESH: Betacoronavirus RNA Viral MESH: Genome Viral Coronavirus Infections MESH: Cytidine medicine.drug MESH: Antiviral Agents MESH: Pandemics MESH: Mutation exonuclease MESH: Alanine CoV Pneumonia Viral antisense oligonucleotide (ASO) Computational biology Genome Viral Biology Therapeutic targeting Hydroxylamines Antiviral Agents Article ASO 03 medical and health sciences Betacoronavirus MESH: Severity of Illness Index Coronavirus (CoV) medicine Humans MESH: SARS-CoV-2 anti-coronavirus drugs Molecular Biology Pandemics 030304 developmental biology Exonuclease (ExoN) MESH: Ribonucleosides MESH: Humans Nucleoside analogue SARS-CoV-2 MESH: Transcription Genetic MESH: Virus Replication nucleoside analog RNA COVID-19 Correction MESH: Hydroxylamines Cell Biology Amides Adenosine Monophosphate non-structural protein 14 (nsp14) respiratory tract diseases nucleoside analogue (NA) Viral replication chemistry MESH: Pneumonia Viral Mutation nsp14 MESH: Viral Nonstructural Proteins NA Ribonucleosides 030217 neurology & neurosurgery |
| Zdroj: | Molecular Cell Molecular Cell, Elsevier, 2020, 79 (5), pp.710-727. ⟨10.1016/j.molcel.2020.07.027⟩ Molecular Cell, 2020, 79 (5), pp.710-727. ⟨10.1016/j.molcel.2020.07.027⟩ |
| ISSN: | 1097-4164 1097-2765 |
| DOI: | 10.1016/j.molcel.2020.07.027⟩ |
| Popis: | Summary The coronavirus disease 2019 (COVID-19) that is wreaking havoc on global public health and economies has heightened awareness about the lack of effective antiviral treatments for human coronaviruses (CoVs). Many current antivirals, notably nucleoside analogues (NA), exert their effect by incorporation into viral genomes and subsequent disruption of viral replication and fidelity. The development of anti-CoV drugs has long been hindered by the capacity of CoVs to proofread and remove mismatched nucleotides during genome replication and transcription. Here, we review the molecular basis of the CoV proofreading complex and evaluate its potential as a drug target. We also consider existing nucleoside analogues and novel genomic techniques as potential anti-CoV therapeutics that could be used individually or in combination to target the proofreading mechanism. Graphical Abstract Robson et al. examine the molecular basis of the coronavirus proofreading mechanism and how this contributes to the resistance of this family of viruses to nucleoside analogue (NA) antiviral drugs. They discuss antisense oligonucleotide (ASO) therapy in combination with NAs to potentially improve the potency and delivery of antiviral drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|